Amplia Therapeutics Limited (ATX:ASX)

21.0¢

right-arrow Created with Sketch. 0.005 (2.44%)
MCAP $25.58M
Last trade 13.00pm 17/09/2021 20mins delayed

Latest Announcements

15/09/2021 Price SensitivePSATXAmplia Therapeutics Limited
15/09/2021ATXAmplia Therapeutics Limited
06/09/2021ATXAmplia Therapeutics Limited
27/08/2021ATXAmplia Therapeutics Limited
27/08/2021 Price SensitivePSATXAmplia Therapeutics Limited
20/08/2021ATXAmplia Therapeutics Limited
28/07/2021 Price SensitivePSATXAmplia Therapeutics Limited
26/07/2021ATXAmplia Therapeutics Limited

Company Overview

Amplia Therapeutics Limited is an Australia-based clinical-stage drug development company. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).

ATX in the news

Amplia Therapeutics (ATX) completes the design for a Phase 2 clinical trial…
Results from Amplia Therapeutics’ (ATX) recent clinical trial shows its treatment for…
Amplia Therapeutics (ATX) has received new data on its treatment for pancreatic cancer in…
Amplia Therapeutics (ATX) has completed a private placement and is set to…

Search Previous Announcements